FX.co ★ GSK Reports Expanded Approval For Jemperli Plus Chemotherapy

GSK plc (GSK, GSK.L) announced that the FDA has approved Jemperli for use in combination with carboplatin and paclitaxel, followed by Jemperli as a monotherapy, for the treatment of adult patients with primary advanced or recurrent endometrial cancer. This approval extends the previous indication to now include patients with mismatch repair-proficient/microsatellite stable tumors, who constitute 70-75% of those diagnosed with endometrial cancer.

Jemperli was discovered by AnaptysBio and subsequently licensed to TESARO under a collaboration and exclusive license agreement established in March 2014. GSK is currently responsible for the research, development, commercialization, and manufacturing of both Jemperli and cobolimab.